Brief: Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response Rate
30/03/2026 12:59
March 30 (Reuters) - Medicus Pharma Ltd MDCX.O: MEDICUS PHARMA REPORTS KOL VALIDATION OF SKINJECT PHASE 2 DATA OF 80% OVERALL RESPONSE RATE Source text: ID:nGNX8ThB6m Further company coverage: MDCX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer